Rein Therapeutics Inc (NASDAQ:RNTX) — Market Cap & Net Worth
Market Cap & Net Worth: Rein Therapeutics Inc (RNTX)
Rein Therapeutics Inc (NASDAQ:RNTX) has a market capitalization of $67.51 Million ($67.51 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20840 globally and #4707 in its home market, demonstrating a -4.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rein Therapeutics Inc's stock price $0.79 by its total outstanding shares 85539032 (85.54 Million). Also see Rein Therapeutics Inc assets under control for a full breakdown of the balance sheet.
Rein Therapeutics Inc Market Cap History: 2025 to 2026
Rein Therapeutics Inc's market capitalization history from 2025 to 2026. Data shows change from $99.23 Million to $67.51 Million (-42.45% CAGR). Also see RNTX cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Rein Therapeutics Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #597 of 976 |
Weight: Rein Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rein Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rein Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Rein Therapeutics Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RNTX by Market Capitalization
Companies near Rein Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review Rein Therapeutics Inc tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Rein Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Rein Therapeutics Inc Historical Marketcap From 2025 to 2026
Between 2025 and today, Rein Therapeutics Inc's market cap moved from $99.23 Million to $ 67.51 Million, with a yearly change of -42.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $67.51 Million | -31.97% |
| 2025 | $99.23 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Rein Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $67.51 Million USD |
| MoneyControl | $67.51 Million USD |
| MarketWatch | $67.51 Million USD |
| marketcap.company | $67.51 Million USD |
| Reuters | $67.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rein Therapeutics Inc
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b a… Read more